Newsletter Tool

Today's Rundown

Sanofi, scarred by Roche scrap, hits goal in once-weekly hemophilia A trial and plots race to regulators
ViVE 2022: Amazon Pharmacy teams up with Blue Plans in 5 states to roll out prescription discount savings card
Medtronic, FDA expand HawkOne atherectomy recall to include TurboHawk Plus catheters
That key Gilead breast cancer readout? Try 2024, and don't get your hopes up: analyst
AbbVie, Alvotech settle Humira patent and trade secrets disputes, teeing up another biosim rollout next year
Adaptive Biotechnologies lays off 12% of workforce to narrow immunosequencing tech
RISE 2022: Health plans grapple with how to acquire, implement health equity data
Saluda's spinal cord stimulation system scores FDA approval for chronic pain
With FDA AdComm on the books, Acadia sees glimmer of hope in second stab at Alzheimer’s psychosis
J&J's long-acting injectable push barrels forward as it adds 2nd large molecule to Midatech pact
Congress to grant 5-month extension for pandemic telehealth flexibilities with omnibus bill
Enough with data collection, FDA needs diversity policies to boost representation in clinical trials: report
J&J inks vaccine licensing deal with Aspen, paving the way for Africa's first local COVID-19 shot

Featured Story

Sanofi, scarred by Roche scrap, hits goal in once-weekly hemophilia A trial and plots race to regulators

By Nick Paul Taylor

Sanofi is fighting back against Roche in the hemophilia A market. Having seen Hemlibra eat into sales of its long-acting factor VIII (FVIII) therapy, Sanofi has now posted positive phase 3 data on its once-weekly successor, positioning the French pharma and partner Sobi to start filing for approvals.

ViVE 2022: Amazon Pharmacy teams up with Blue Plans in 5 states to roll out prescription discount savings card

By Heather Landi

MIAMI—Amazon Pharmacy is partnering with Blue Plans in five states and Prime Therapeutics to tackle the affordability of prescription medications. The online retail giant's pharmacy arm is rolling out a prescription discount savings card that's available to some Blue Plans members.

Medtronic, FDA expand HawkOne atherectomy recall to include TurboHawk Plus catheters

By Conor Hale

The previous recall covered more than 95,000 devices for Medtronic’s HawkOne system after it was discovered that the catheter’s guidewire could bend during use.

That key Gilead breast cancer readout? Try 2024, and don't get your hopes up: analyst

By Angus Liu

Gilead Sciences just tipped off what sounded like mixed results for Trodelvy, the cornerstone of the Big Biotech’s oncology ambitions. Now, one analyst suggests investors continue to keep their expectations low for the key expansion opportunity⁠—at least for now.

AbbVie, Alvotech settle Humira patent and trade secrets disputes, teeing up another biosim rollout next year

By Fraiser Kansteiner

Under the deal, Alvotech could launch its Humira copycat as early as next summer. AbbVie will grant Alvotech a license to its Humira-related patents in the U.S., which take effect on July 1, 2023. Alvotech is on deck to pay royalties to AbbVie and it “acknowledges the validity and enforceability of the licensed patents,” AbbVie said in a release.

PM Tracker

Featured Story

Sanofi, scarred by Roche scrap, hits goal in once-weekly hemophilia A trial and plots race to regulators

Top Stories

ViVE 2022: Amazon Pharmacy teams up with Blue Plans in 5 states to roll out prescription discount savings card

Medtronic, FDA expand HawkOne atherectomy recall to include TurboHawk Plus catheters

That key Gilead breast cancer readout? Try 2024, and don't get your hopes up: analyst

AbbVie, Alvotech settle Humira patent and trade secrets disputes, teeing up another biosim rollout next year

Adaptive Biotechnologies lays off 12% of workforce to narrow immunosequencing tech

RISE 2022: Health plans grapple with how to acquire, implement health equity data

Saluda's spinal cord stimulation system scores FDA approval for chronic pain

With FDA AdComm on the books, Acadia sees glimmer of hope in second stab at Alzheimer’s psychosis

J&J's long-acting injectable push barrels forward as it adds 2nd large molecule to Midatech pact

Congress to grant 5-month extension for pandemic telehealth flexibilities with omnibus bill

Enough with data collection, FDA needs diversity policies to boost representation in clinical trials: report

J&J inks vaccine licensing deal with Aspen, paving the way for Africa's first local COVID-19 shot